Sign in →

Test Code NGPLSB OncoPlus, Universal Cancer Mutation Analysis Panel (NGS), (Blood)

Important Note

Starting on 01/09/2017, the University of Chicago Molecular Pathology Laboratory launched an updated version of the OncoPlus universal cancer mutation analysis panel. This is a Next Generation Sequencing assay designed to interrogate over 1,200 solid tumor and hematological malignancy related genes via analysis of Peripheral Blood, Bone Marrow, Formalin-Fixed Paraffin-Embedded and Cytology Smear specimens. 28 additional genes were added to the previously 119 clinically reported genes.

In addition, this updated panel version allows:

  • The detection and reporting of copy number variations (CNVs) for 136 genes.
  • The detection and reporting of lung cancer-related gene fusions in ALK, RET, and ROS1.

Specimen Type

Blood

Container/Tube

Lavender top

Offsite Collection Instructions

Send within 24 hours or Refrigerate/ send within 72 hours

Turnaround Time

15 Days

Preferred Volume

10 mL

UCMC Collection Instructions

Send within 24 hours or Refrigerate/ send within 72 hours

Test Usage

Comprehensive assay for cancer genomic of solid tumor and
hematological malignancy specimens to determine appropriate
therapies. It also can be useful for diagnosis, prognosis,
clinical
trials selection and for translational research.

Critical Results

None

Additional Information

  • Appropriate specimens should contain >20% tumor cells
    and
    enough total cells to produce adequate DNA yield (typically
    >50,000 total cells).
  • Specimens with less than 20% tumor cells may be tested at
    the
    discretion of the attending molecular pathologist.

 

Fee Code

376540-30081450

STAT Turnaround Time

Not Available

Specimen Stability

72 Hours

Specimen Minimum Volume

1 mL

Special Instructions

Send within 72 hours

DAY(S) AND TIME(S) PERFORMED

Monday – Friday, 8:00 AM – 4:30 PM

STAT DAY(S) AND TIME(S) PERFORMED

No

CPT

81450

Method Name

Next Generation Sequencing

Reference Values

Interpretative report

Reject Due To

Inappropriate anticoagulant and >72 hours